That is my thinking as well. The Phase 2b trial with over 300 participants (not 30) went very well, and moving to 900 in Phase 3 with a nearly identical protocol is, mathematically speaking, almost a sure thing mathematically speaking to see a reproduction of the Phase 2b results in Phase 3. So, the risk sits outside of mathematical predictions
As many here have mentioned, there are no sure bets in Phase 3 trials, but I am at a loss as to what the high-IQ analysts internally at the big pharma could be imagining. Or perhaps OPT has rejected their multibillion-dollar advances.
Certainly, I'm thinking of big buy if OPT's stock gets into the 40s.
Interesting speculation that a low stock price may force OPT's hand into accepting a bad deal as the possibility of a CR is diminished.
- Forums
- ASX - By Stock
- OPT
- Ann: Opthea Completes Enrollment in Phase 3 Clinical Program
Ann: Opthea Completes Enrollment in Phase 3 Clinical Program, page-21
-
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $398.3M |
Open | High | Low | Value | Volume |
37.0¢ | 37.8¢ | 36.0¢ | $480.8K | 1.298M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 34921 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 14866 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 34921 | 0.365 |
8 | 236282 | 0.360 |
7 | 299234 | 0.355 |
10 | 220315 | 0.350 |
3 | 49105 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 14866 | 6 |
0.375 | 18512 | 1 |
0.380 | 18512 | 2 |
0.385 | 96007 | 2 |
0.390 | 11703 | 3 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |